Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application - Global Forecast to 2028
상품코드:1397373
리서치사:MarketsandMarkets
발행일:2023년 12월
페이지 정보:영문 197 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
보고서 개요
조사 범위
조사 대상연도
2021-2028년
기준연도
2022년
예측 기간
2023-2028년
단위
금액(달러)
부문
세포원, 유형, 치료 용도, 지역
대상 지역
북미·유럽·아시아 태평양·남미·중동 및 아프리카
세계의 줄기세포 치료(Stem Cell Therapy) 시장 규모는 2023년 2억 8,600만 달러에서 예측 기간 동안 16.5%의 CAGR로 성장을 지속하여 2028년에는 6억 1,500만 달러 규모에 달할 것으로 예측됩니다.
주요 진입 사업자는 다양한 질병에 대한 새로운 줄기세포 치료의 개발에 주력하고 있으며, 이는 향후 수년간 시장 성장에 영향을 줄 수 있는 주요 요인 중 하나입니다. 지난 수년간 줄기세포 치료에 대한 FDA의 승인이 증가하고 있으며 임상시험 건수가 대폭 증가하고 있는 것도 시장 성장에 탄력을 줄 것으로 예상됩니다.
유형별로, 동종 줄기세포의 부문은 2022년에 압도적인 점유율을 보여줍니다. 동종 줄기세포 치료는 하나의 세포원으로부터 많은 용량을 얻을 수 있기 때문에 경제적으로 실행 가능하고 시간이 걸리지 않습니다. 현재 10종 이상의 동종 줄기세포 치료가 상업화되어 전 세계에서 승인되고 있습니다.
세포원별로는 지방조직 유래 MSC 부문이 2022년에 압도적인 점유율을 획득했습니다. 한편, 예측 기간 동안 골수 유래 MSC 부문이 대폭적인 CAGR로 성장할 것으로 예측됩니다. 골수 유래 MSC는 줄기세포 치료에 가장 선호되는 유형입니다. 골수유래 MSC의 입수가 용이하다는 것, 체외처리에 필요한 시간이 짧은 것 등이, 동세포의 이용에 탄력을 주어, 동부문의 성장을 촉진하는 주된 요인이 되고 있습니다.
지역별로는 아시아 태평양이 예측 기간 동안 높은 CAGR로 성장할 것으로 예측됩니다. 한국에서는 줄기세포 치료에 대한 정부의 승인이 높아지고 있습니다. 또한 이 지역의 줄기세포 치료 개발을 위한 산업계와의 제휴는 이 지역 시장 성장을 더욱 가속시킬 수 있습니다.
세계의 줄기세포 치료(Stem Cell Therapy) 시장을 조사했으며, 시장 개요/시장 성장에 대한 다양한 영향 요인 및 시장 기회 분석/기술 및 특허 동향/파이프라인 분석/법 규제 환경/시장 규모 추이 및 예측/각종 구분·지역별 상세 분석/경쟁 구도/주요 기업 개요 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
시장 역학
성장 촉진요인
억제요인
기회
과제
기술 분석
고객의 사업에 영향을 미치는 동향·혁신
밸류체인 분석
에코시스템 시장 맵
공급망 분석
Porter's Five Forces 분석
규제 분석
가격 분석
특허 분석
주요 회의 및 이벤트
파이프라인 분석
주요 이해관계자와 구매 기준
제6장 줄기세포 치료 시장 : 세포원별
지방 조직 유래 MSC(간엽계 줄기세포)
골수 유래 MSC(간엽계 줄기세포)
태반·제대 유래 MSC(간엽계 줄기세포)
기타
제7장 줄기세포 치료 시장 : 유형별
동종 줄기세포 치료
자가 줄기세포 치료
제8장 줄기세포 치료 시장 : 치료 용도별
근골격계 질환
상처·수술
염증성 질환·자가면역 질환
심혈관 질환
신경장애
기타
제9장 줄기세포 치료 시장 : 지역별
북미
유럽
아시아 태평양
기타 지역
제10장 경쟁 구도
주요 기업의 채택 전략
수익 점유율 분석
시장 점유율 분석
기업 평가 매트릭스
주요 기업의 경쟁 벤치마킹
상위 15개사의 지역별 실적
스타트업/중소기업 평가 매트릭스
스타트업/중소기업 경쟁 벤치마킹
경쟁 시나리오 및 동향
제11장 기업 개요
주요 기업
SMITH NEPHEW
MEDIPOST
JCR PHARMACEUTICALS CO., LTD.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
ANTEROGEN CO., LTD.
CORESTEM, INC.
PHARMICELL CO., LTD
NUVASIVE, INC.
RTI SURGICAL
ALLOSOURCE
HOLOSTEM TERAPIE AVANZATE SRL
ORTHOFIX MEDICAL INC.
STEMPEUTICS RESEARCH PVT LTD.
REGROW BIOSCIENCES PVT LTD.
기타 기업
ATHERSYS, INC.
MESOBLAST LTD.
BIORESTORATIVE THERAPIES, INC.
PLURISTEM THERAPEUTICS INC.
BRAINSTORM CELL LIMITED
GAMIDA CELL
VIACYTE, INC.
KANGSTEM BIOTECH CO., LTD.
HOPE BIOSCIENCES
CELLULAR BIOMEDICINE GROUP
PERSONALIZED STEM CELLS
제12장 부록
LYJ
영문 목차
영문목차
Report Description
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Million
Segments
Cell Source, Type, Therapeutic Application and Region
Regions covered
North America, Europe, Asia Pacific, Latin America, the Middle East and Africa
The global stem cell therapy market is projected to reach USD 615 million by 2028 from USD 286 million in 2023, at a CAGR of 16.5% during the forecast period. Key market players are focusing on developing new stem cell therapies for various disease conditions this is one of the major factor is likely to impact the market growth in coming years. The increasing number of clinical trials has largely in past few years coupled with rise in FDA approvals for stem cell therapy is anticipated to give momentum to the market growth.
"The allogeneic stem cell segment accounted dominant share in 2022"
The stem cell therapy market is segmented into allogeneic and autologous. Allogeneic segment accounted for the dominant share in 2022. In allogeneic stem cell therapy, one cell source can produce numerous doses, thus making allogeneic therapy economically viable and less time-consuming, these are some of the major elements responsible for the doninat share of the segment. Presently, more than ten approved commercialized allogeneic stem cell therapies are available globally.
"Bone Marrow-derived MSCs segment is anticipated to grow at significant CAGR"
Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. In 2022, the adipose tissue-derived MSCs segment gained dominant share in the stem cell therapy market. Bone marrow-derived mesenchymal stem cells most preferred type for are stem cell therapies. Easy availability of Bone marrow MSCs and less time required for in-vitro processing are some of the major factorslikely to give momentum to the use of bone marrow derived MSCs uplifting the segmental growth.
"Asia Pacific region is likely to grow at a faster pace."
The stem cell therapy market is segmented into North America, Europe, Asia Pacific and Rest of the world. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for stem cell therapy in South Korea. Furthermore, industrial collabrations in the region for stem cell therapy development is further likely to give pace for the market growth in the region. For instance, Reyon Pharmaceutical and Therabest entered into a joint development agreement for NK cell therapy for treating solid cancer. Under this agreement, the two companies will jointly develop iPSC (induced pluripotent stem cell)-derived NK cell therapy 'TB-100' for solid cancer indications.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 80%, and Demand Side - 20%
By Region: North America -40%, Asia-Pacific -20%, Europe -30%, ROW-10%
List of Companies Profiled in the Report:
Smith+Nephew (UK)
MEDIPOST Co. Ltd. (South Korea)
Anterogen Co. Ltd. (South Korea)
CORESTEM (South Korea)
Pharmicell Co. Ltd. (South Korea)
NuVasive Inc. (US)
RTI Surgical (US)
AlloSource (US)
JCR Pharmaceuticals Co. Ltd. (Japan)
Takeda Pharmaceutical Company Limited (Japan)
Holostem Terapie Avanzate Srl (Italy)
Orthofix (US)
Regrow Biosciences Pvt Ltd. (India)
STEMPEUTICS RESEARCH PVT LTD. (India)
Athersys (US)
Mesoblast Ltd (Australia)
Biorestorative Therapies Inc. (US)
Pluristem Inc. (Israel)
Brainstorm Cell Limited. (US)
ViaCyte Inc. (US)
Gamida Cell (US)
Kangstem Biotech (South Korea)
Hope Biosciences (US)
Cellular Biomedicine Group (US)
Personalized Stem Cells (US)
Research Coverage:
This report provides a detailed picture of the stem cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.
Product Development/Innovation: Detailed insights on newly launched products of the stem cell therapy market.
Market Development: Comprehensive information about lucrative markets - the report analyses the stem cell therapy market across varied regions.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the stem cell therapy market.
Pipeline Analysis: Detailed information on stem cell therapy under phase 3 clinical trials.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Smith+Nephew (UK), MEDIPOST Co. Ltd. (South Korea), Anterogen Co. Ltd. (South Korea), CORESTEM (South Korea) and among others in the stem cell therapy market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 YEARS CONSIDERED
1.5 CURRENCY
1.6 RESEARCH LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.9 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2022
TABLE 131 STEM CELL THERAPY MARKET: DEALS, JANUARY 2020-OCTOBER 2023
10.10.3 OTHER DEVELOPMENTS
TABLE 132 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020-OCTOBER 2023
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
11.1 KEY PLAYERS
11.1.1 SMITH+NEPHEW
TABLE 133 SMITH+NEPHEW: BUSINESS OVERVIEW
FIGURE 34 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
11.1.2 MEDIPOST
TABLE 134 MEDIPOST: BUSINESS OVERVIEW
FIGURE 35 MEDIPOST: COMPANY SNAPSHOT (2021)
11.1.3 JCR PHARMACEUTICALS CO., LTD.
TABLE 135 JCR PHARMACEUTICALS CO., LTD.: BUSINESS OVERVIEW
FIGURE 36 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2022)
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 136 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
11.1.5 ANTEROGEN CO., LTD.
TABLE 137 ANTEROGEN CO., LTD.: BUSINESS OVERVIEW
11.1.6 CORESTEM, INC.
TABLE 138 CORESTEM INC.: BUSINESS OVERVIEW
FIGURE 38 CORESTEM INC.: COMPANY SNAPSHOT (2021)
11.1.7 PHARMICELL CO., LTD
TABLE 139 PHARMICELL CO., LTD: BUSINESS OVERVIEW
11.1.8 NUVASIVE, INC.
TABLE 140 NUVASIVE, INC.: BUSINESS OVERVIEW
FIGURE 39 NUVASIVE, INC.: COMPANY SNAPSHOT (2022)
11.1.9 RTI SURGICAL
TABLE 141 RTI SURGICAL: BUSINESS OVERVIEW
11.1.10 ALLOSOURCE
TABLE 142 ALLOSOURCE: BUSINESS OVERVIEW
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL
TABLE 143 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW
11.1.12 ORTHOFIX MEDICAL INC.
TABLE 144 ORTHOFIX MEDICAL INC.: BUSINESS OVERVIEW
FIGURE 40 ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT (2022)
11.1.13 STEMPEUTICS RESEARCH PVT LTD.
TABLE 145 STEMPEUTICS RESEARCH PVT LTD.: BUSINESS OVERVIEW
11.1.14 REGROW BIOSCIENCES PVT LTD.
TABLE 146 REGROW BIOSCIENCES PVT LTD.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 ATHERSYS, INC.
TABLE 147 ATHERSYS, INC.: BUSINESS OVERVIEW
11.2.2 MESOBLAST LTD.
TABLE 148 MESOBLAST LTD.: BUSINESS OVERVIEW
11.2.3 BIORESTORATIVE THERAPIES, INC.
TABLE 149 BIORESTORATIVE THERAPIES, INC.: BUSINESS OVERVIEW
11.2.4 PLURISTEM THERAPEUTICS INC.
TABLE 150 PLURISTEM THERAPEUTICS INC.: BUSINESS OVERVIEW
11.2.5 BRAINSTORM CELL LIMITED
TABLE 151 BRAINSTORM CELL LIMITED: BUSINESS OVERVIEW
11.2.6 GAMIDA CELL
TABLE 152 GAMIDA CELL: BUSINESS OVERVIEW
11.2.7 VIACYTE, INC.
TABLE 153 VIACYTE, INC.: BUSINESS OVERVIEW
11.2.8 KANGSTEM BIOTECH CO., LTD.
TABLE 154 KANGSTEM BIOTECH CO., LTD.: BUSINESS OVERVIEW
11.2.9 HOPE BIOSCIENCES
TABLE 155 HOPE BIOSCIENCES: BUSINESS OVERVIEW
11.2.10 CELLULAR BIOMEDICINE GROUP
TABLE 156 CELLULAR BIOMEDICINE GROUP: BUSINESS OVERVIEW
11.2.11 PERSONALIZED STEM CELLS
TABLE 157 PERSONALIZED STEM CELLS: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
